Therapeutic potential of peptide toxins that target ion channels

Inflammation and Allergy - Drug Targets

Volumn 10, Issue 5, 2011, Pages 322-342

  Beraud, Evelyne ^a   Chandy, K George ^b  

^a University of the Mediterranean Aix Marseille II   (France)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Autoimmune disease; Immunomodulation; Ion channels; Pain; Peptide toxins; Venom

Indexed keywords

CHARYBDOTOXIN; CLOFAZIMINE; CONANTOKIN G; DENDROTOXIN; HETEROPODATOXIN; HONGOTOXIN; ION CHANNEL; KALIOTOXIN; MARGATOXIN; MAST CELL DEGRANULATING PEPTIDE; NOXIUSTOXIN; OMEGA CONOTOXIN; OMEGA CONOTOXIN CVID; OMEGA CONOTOXIN MVIB; OMEGA CONOTOXIN MVIIA; PEPTIDE DERIVATIVE; PEPTIDE TOXIN; PHRIXOTOXIN 2; POTASSIUM CHANNEL KV1.3; SAXITOXIN; SCORPION VENOM; SEA ANEMONE TOXIN; SNAKE VENOM; SPIDER VENOM; TETRODOTOXIN; TITYUS TOXIN; TOXIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENOM; VOLTAGE DEPENDENT ANION CHANNEL;

ALLERGIC ENCEPHALOMYELITIS; AUTOIMMUNE DISEASE; CANCER PAIN; CHINA; CHRONIC PAIN; DELAYED HYPERSENSITIVITY; DISEASE COURSE; DRUG TARGETING; EDITORIAL; HEART PROTECTION; HUMAN; INFLAMMATION; NEOPLASM; NEUROLOGIC DISEASE; NONHUMAN; PAIN; PUSTULAR PSORIASIS; RHEUMATOID ARTHRITIS; SCORPION; SEA ANEMONE; SKIN LUPUS ERYTHEMATOSUS; SNAIL; SNAKE; SPIDER;

EID: 80052847726     PISSN: 18715281     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152811797200696     Document Type: Editorial

References (317)

1. Lewis, R. J. Conotoxins: molecular and therapeutic targets. Prog. Mol. Subcell. Biol., 2009, 46, 45-65.
2. Olivera, B. M. Conus peptides: biodiversity-based discovery and exogenomics. J. Biol. Chem., 2006, 281 (42), 31173-31177.
3. Twede, V. D.; Miljanich, G.; Olivera, B. M.; Bulaj, G. Neuroprotective and cardioprotective conopeptides: an emerging class of drug leads. Curr. Opin. Drug Discov. Devel., 2009, 12 (2), 231-239.
4. Mouhat, S.; Andreotti, N.; Jouirou, B.; Sabatier, J. M. Animal toxins acting on voltage-gated potassium channels. Curr. Pharm. Des., 2008, 14 (24), 2503-2518.
5. Swartz, K. J., Tarantula toxins interacting with voltage sensors in potassium channels. Toxicon, 2007, 49 (2), 213-230.
6. Possani, L. D.; Merino, E.; Corona, M.; Bolivar, F.; Becerril, B. Peptides and genes coding for scorpion toxins that affect ionchannels. Biochimie, 2000, 82 (9/10), 861-868.
7. Goudet, C.; Chi, C. W.; Tytgat, J. An overview of toxins and genes from the venom of the Asian scorpion Buthus martensi Karsch. Toxicon 2002, 40 (9), 1239-1258.
8. Shiomi, K. Novel peptide toxins recently isolated from sea anemones. Toxicon, 2009, 54 (8), 1112-1128.
9. Bowersox, S. S.; Singh, T.; Nadasdi, L.; Zukowska-Grojec, Z.; Valentino, K.; Hoffman, B. B. Cardiovascular effects of omegaconopeptides in conscious rats: mechanisms of action. J. Cardiovasc. Pharmacol., 1992, 20 (5), 756-764.
10. Glaser, K. B.; Mayer, A. M. A renaissance in marine pharmacology: from preclinical curiosity to clinical reality. Biochem. Pharmacol., 2009, 78 (5), 440-448.
11. Hama, A.; Sagen, J. Antinociceptive effects of the marine snail peptides conantokin-G and conotoxin MVIIA alone and in combination in rat models of pain. Neuropharmacology, 2009, 56 (2), 556-563.
12. Kristipati, R.; Nadasdi, L.; Tarczy-Hornoch, K.; Lau, K.; Miljanich, G. P.; Ramachandran, J.; Bell, J. R. Characterization of the binding of omega-conopeptides to different classes of non-Ltype neuronal calcium channels. Mol. Cell. Neurosci., 1994, 5 (3), 219-228.
13. Nadasdi, L.; Yamashiro, D.; Chung, D.; Tarczy-Hornoch, K.; Adriaenssens, P.; Ramachandran, J. Structure-activity analysis of a Conus peptide blocker of N-type neuronal calcium channels. Biochemistry, 1995, 34 (25), 8076-8081.
14. Xiao, W. H.; Bennett, G. J. Synthetic omega-conopeptides applied to the site of nerve injury suppress neuropathic pains in rats. J. Pharmacol. Exp. Ther., 1995, 274 (2), 666-672.
15. Schroeder, C. I.; Doering, C. J.; Zamponi, G. W.; Lewis, R. J. Ntype calcium channel blockers: novel therapeutics for the treatment of pain. Med. Chem., 2006, 2 (5), 535-543.
16. Smith, M. T.; Cabot, P. J.; Ross, F. B.; Robertson, A. D.; Lewis, R. J. The novel N-type calcium channel blocker, AM336, produces potent dose-dependent antinociception after intrathecal dosing in rats and inhibits substance P release in rat spinal cord slices. Pain, 2002, 96 (1-2), 119-127.
17. Malmberg, A. B.; Gilbert, H.; McCabe, R. T.; Basbaum, A. I. Powerful antinociceptive effects of the cone snail venom-derived subtype-selective NMDA receptor antagonists conantokins G and T. Pain, 2003, 101 (1-2), 109-216.
18. Xiao, C.; Huang, Y.; Dong, M.; Hu, J.; Hou, S.; Castellino, F. J.; Prorok, M.; Dai, Q. NR2B-selective conantokin peptide inhibitors of the NMDA receptor display enhanced antinociceptive properties compared to non-selective conantokins. Neuropeptides, 2008, 42 (5/6), 601-609.
19. Williams, A. J.; Ling, G.; McCabe, R. T.; Tortella, F. C. Intrathecal CGX-1007 is neuroprotective in a rat model of focal cerebral ischemia. Neuroreport, 2002, 13 (6), 821-824.
20. Deshane, J.; Garner, C. C.; Sontheimer, H. Chlorotoxin inhibits glioma cell invasion via matrix metalloproteinase-2. J. Biol. Chem., 2003, 278 (6), 4135-4144.
21. Sontheimer, H., An unexpected role for ion channels in brain tumor metastasis. Exp. Biol. Med. (Maywood) 2008, 233 (7), 779-791.
22. Bulaj, G.; Zhang, M. M.; Green, B. R.; Fiedler, B.; Layer, R. T.; Wei, S.; Nielsen, J. S.; Low, S. J.; Klein, B. D.; Wagstaff, J. D.; Chicoine, L.; Harty, T. P.; Terlau, H.; Yoshikami, D.; Olivera, B. M. Synthetic muO-conotoxin MrVIB blocks TTX-resistant sodium channel NaV1.8 and has a long-lasting analgesic activity. Biochemistry, 2006, 45 (23), 7404-7414.
23. Daly, N. L.; Ekberg, J. A.; Thomas, L.; Adams, D. J.; Lewis, R. J.; Craik, D. J. Structures of muO-conotoxins from Conus marmoreus. I nhibitors of tetrodotoxin (TTX)-sensitive and TTX-resistant sodium channels in mammalian sensory neurons. J Biol. Chem., 2004, 279 (24), 25774-25782.
24. Lubbers, N. L.; Campbell, T. J.; Polakowski, J. S.; Bulaj, G.; Layer, R. T.; Moore, J.; Gross, G. J.; Cox, B. F. Postischemic administration of CGX-1051, a peptide from cone snail venom, reduces infarct size in both rat and dog models of myocardial ischemia and reperfusion. J. Cardiovasc. Pharmacol., 2005, 46 (2), 141-146.
25. Zhang, S. J.; Yang, X. M.; Liu, G. S.; Cohen, M. V.; Pemberton, K.; Downey, J. M. CGX-1051, a peptide from Conus snail venom, attenuates infarction in rabbit hearts when administered at reperfusion. J. Cardiovasc. Pharmacol., 2003,42 (6), 764-771.
26. Catterall, W. A. Structure and regulation of voltage-gated Ca2+ channels. Annu. Rev. Cell Dev. Biol., 2000, 16, 521-555.
27. Hirning, L. D.; Fox, A. P.; McCleskey, E. W.; Olivera, B. M.; Thayer, S. A.; Miller, R. J.; Tsien, R. W. Dominant role of N-type Ca2+ channels in evoked release of norepinephrine from sympathetic neurons. Science, 1988, 239 (4835), 57-61.
28. Turner, T. J.; Adams, M. E.; Dunlap, K. Multiple Ca2+ channel types coexist to regulate synaptosomal neurotransmitter release. Proc. Natl. Acad. Sci. USA, 1993, 90 (20), 9518-9522.
29. Monnier, N.; Procaccio, V.; Stieglitz, P.; Lunardi, J. Malignanthyperthermia susceptibility is associated with a mutation of the alpha 1-subunit of the human dihydropyridine-sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle. Am. J. Hum. Genet., 1997, 60 (6), 1316-1325.
30. Chaudhari, N. A single nucleotide deletion in the skeletal musclespecific calcium channel transcript of muscular dysgenesis (mdg) mice. J. Biol. Chem., 1992, 267 (36), 25636-25639.
31. Jurkat-Rott, K.; Lehmann-Horn, F.; Elbaz, A.; Heine, R.; Gregg, R. G.; Hogan, K.; Powers, P. A.; Lapie, P.; Vale-Santos, J. E.; Weissenbach, J. A calcium channel mutation causing hypokalemic periodic paralysis. Hum. Mol. Genet., 1994, 3 (8), 1415-1419.
32. Ptacek, L. J.; Tawil, R.; Griggs, R. C.; Engel, A. G.; Layzer, R. B.; Kwiecinski, H.; McManis, P. G.; Santiago, L.; Moore, M.; Fouad, G. Dihydropyridine receptor mutations cause hypokalemic periodic paralysis. Cell, 1994, 77 (6), 863-868.
33. Splawski, I.; Timothy, K. W.; Sharpe, L. M.; Decher, N.; Kumar, P.; Bloise, R.; Napolitano, C.; Schwartz, P. J.; Joseph, R. M.; Condouris, K.; Tager-Flusberg, H.; Priori, S. G.; Sanguinetti, M. C.; Keating, M. T. Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell, 2004, 119 (1), 19-31.
34. Bech-Hansen, N. T.; Naylor, M. J.; Maybaum, T. A.; Pearce, W. G.; Koop, B.; Fishman, G. A.; Mets, M.; Musarella, M. A.; Boycott, K. M. Loss-of-function mutations in a calcium-channel alpha1-subunit gene in Xp11.23 cause incomplete X-linked congenital stationary night blindness. Nat. Genet., 1998, 19 (3), 264-267.
35. Strom, T. M.; Nyakatura, G.; Apfelstedt-Sylla, E.; Hellebrand, H.; Lorenz, B.; Weber, B. H.; Wutz, K.; Gutwillinger, N.; Ruther, K.; Drescher, B.; Sauer, C.; Zrenner, E.; Meitinger, T.; Rosenthal, A.; Meindl, A. An L-type calcium-channel gene mutated in incomplete X-linked congenital stationary night blindness. Nat. Genet., 1998, 19 (3), 260-263.
36. Jodice, C.; Mantuano, E.; Veneziano, L.; Trettel, F.; Sabbadini, G.; Calandriello, L.; Francia, A.; Spadaro, M.; Pierelli, F.; Salvi, F.; Ophoff, R. A.; Frants, R. R.; Frontali, M. Episodic ataxia type 2 (EA2) and spinocerebellar ataxia type 6 (SCA6) due to CAG repeat expansion in the CACNA1A gene on chromosome 19p. Hum. Mol. Genet., 1997, 6 (11), 1973-1978.
37. Zhuchenko, O.; Bailey, J.; Bonnen, P.; Ashizawa, T.; Stockton, D. W.; Amos, C.; Dobyns, W. B.; Subramony, S. H.; Zoghbi, H. Y.; Lee, C. C. Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the alpha 1Avoltage- dependent calcium channel. Nat. Genet., 1997, 15 (1), 62-69.
38. Ophoff, R. A.; Terwindt, G. M.; Vergouwe, M. N.; van Eijk, R.; Oefner, P. J.; Hoffman, S. M.; Lamerdin, J. E.; Mohrenweiser, H. W.; Bulman, D. E.; Ferrari, M.; Haan, J.; Lindhout, D.; van Ommen, G. J.; Hofker, M. H.; Ferrari, M. D.; Frants, R. R. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell, 1996, 87 (3), 543-552.
39. Vitko, I.; Chen, Y.; Arias, J. M.; Shen, Y.; Wu, X. R.; Perez-Reyes, E. Functional characterization and neuronal modeling of the effects of childhood absence epilepsy variants of CACNA1H, a T-type calcium channel. J. Neurosci., 2005, 25 (19), 4844-4855.
40. Splawski, I.; Yoo, D. S.; Stotz, S. C.; Cherry, A.; Clapham, D. E.; Keating, M. T. CACNA1H mutations in autism spectrum disorders. J. Biol. Chem., 2006, 281 (31), 22085-22091.
41. Qu, Y.; Baroudi, G.; Yue, Y.; Boutjdir, M. Novel molecular mechanism involving alpha1D (Cav1.3) L-type calcium channel in autoimmune-associated sinus bradycardia. Circulation, 2005, 111 (23), 3034-3041.
42. Chuang, R. S.; Jaffe, H.; Cribbs, L.; Perez-Reyes, E.; Swartz, K. J. Inhibition of T-type voltage-gated calcium channels by a new scorpion toxin. Nat. Neurosci., 1998, 1 (8), 668-674.
43. Sidach, S. S.; Mintz, I. M. Kurtoxin, a gating modifier of neuronal high- and low-threshold Ca channels. J. Neurosci., 2002, 22 (6), 2023-2034.
44. McDonough, S. I.; Boland, L. M.; Mintz, I. M.; Bean, B. P. Interactions among toxins that inhibit N-type and P-type calcium channels. J. Gen. Physiol., 2002, 119 (4), 313-328.
45. Mintz, I. M. Block of Ca channels in rat central neurons by the spider toxin omega-Aga-IIIA. J. Neurosci., 1994, 14 (5 Pt 1), 2844-2853.
46. Bourinet, E.; Soong, T. W.; Sutton, K.; Slaymaker, S.; Mathews, E.; Monteil, A.; Zamponi, G. W.; Nargeot, J.; Snutch, T. P. Splicing of alpha 1A subunit gene generates phenotypic variants of P- and Q-type calcium channels. Nat. Neurosci., 1999, 2 (5), 407-415.
47. Mintz, I. M.; Venema, V. J.; Swiderek, K. M.; Lee, T. D.; Bean, B. P.; Adams, M. E. P-type calcium channels blocked by the spider toxin omega-Aga-IVA. Nature, 1992, 355 (6363), 827-829.
48. Adams, M. E.; Mintz, I. M.; Reily, M. D.; Thanabal, V.; Bean, B. P. Structure and properties of omega-agatoxin IVB, a new antagonist of P-type calcium channels. Mol. Pharmacol., 1993, 44 (4), 681-688.
49. Lampe, R. A.; Defeo, P. A.; Davison, M. D.; Young, J.; Herman, J. L.; Spreen, R. C.; Horn, M. B.; Mangano, T. J.; Keith, R. A. Isolation and pharmacological characterization of omegagrammotoxin SIA, a novel peptide inhibitor of neuronal voltagesensitive calcium channel responses. Mol. Pharmacol., 1993, 44 (2), 451-460.
50. McDonough, S. I.; Lampe, R. A.; Keith, R. A.; Bean, B. P. Voltage-dependent inhibition of N- and P-type calcium channels by the peptide toxin omega-grammotoxin-SIA. Mol. Pharmacol., 1997, 52 (6), 1095-1104.
51. Sutton, K. G.; Siok, C.; Stea, A.; Zamponi, G. W.; Heck, S. D.; Volkmann, R. A.; Ahlijanian, M. K.; Snutch, T. P. Inhibition of neuronal calcium channels by a novel peptide spider toxin, DW13.3. Mol. Pharmacol., 1998, 54 (2), 407-418.
52. Lewis, R. J.; Nielsen, K. J.; Craik, D. J.; Loughnan, M. L.; Adams, D. A.; Sharpe, I. A.; Luchian, T.; Adams, D. J.; Bond, T.; Thomas, L.; Jones, A.; Matheson, J. L.; Drinkwater, R.; Andrews, P. R.; Alewood, P. F. Novel omega-conotoxins from Conus catus discriminate among neuronal calcium channel subtypes. J. Biol. Chem., 2000, 275 (45), 35335-35344.
53. Boland, L. M.; Morrill, J. A.; Bean, B. P. Omega-Conotoxin block of N-type calcium channels in frog and rat sympathetic neurons. J. Neurosci., 1994, 14 (8), 5011-5027.
54. Benjamin, E. R.; Pruthi, F.; Olanrewaju, S.; Shan, S.; Hanway, D.; Liu, X.; Cerne, R.; Lavery, D.; Valenzano, K. J.; Woodward, R. M.; Ilyin, V. I. Pharmacological characterization of recombinant Ntype calcium channel (Cav2.2) mediated calcium mobilization using FLIPR. Biochem. Pharmacol., 2006, 72 (6), 770-782.
55. Kaneko, S.; Cooper, C. B.; Nishioka, N.; Yamasaki, H.; Suzuki, A.; Jarvis, S. E.; Akaike, A.; Satoh, M.; Zamponi, G. W. Identification and characterization of novel human Ca(v)2.2 (alpha 1B) calcium channel variants lacking the synaptic protein interaction site. J. Neurosci., 2002, 22 (1), 82-92.
56. Hillyard, D. R.; Monje, V. D.; Mintz, I. M.; Bean, B. P.; Nadasdi, L.; Ramachandran, J.; Miljanich, G.; Azimi-Zoonooz, A.; McIntosh, J. M.; Cruz, L. J. A new Conus peptide ligand for mammalian presynaptic Ca2+ channels. Neuron, 1992, 9 (1), 69-77.
57. McDonough, S. I.; Swartz, K. J.; Mintz, I. M.; Boland, L. M.; Bean, B. P. Inhibition of calcium channels in rat central and peripheral neurons by omega-conotoxin MVIIC. J. Neurosci., 1996, 16 (8), 2612-2623.
58. Stea, A.; Tomlinson, W. J.; Soong, T. W.; Bourinet, E.; Dubel, S. J.; Vincent, S. R.; Snutch, T. P. Localization and functional properties of a rat brain alpha 1A calcium channel reflect similarities to neuronal Q- and P-type channels. Proc. Natl. Acad. Sci. USA, 1994, 91 (22), 10576-10580.
59. Bourinet, E.; Stotz, S. C.; Spaetgens, R. L.; Dayanithi, G.; Lemos, J.; Nargeot, J.; Zamponi, G. W. Interaction of SNX482 with domains III and IV inhibits activation gating of alpha(1E) (Ca(V)2.3) calcium channels. Biophys. J., 2001, 81 (1), 79-88.
60. Newcomb, R.; Szoke, B.; Palma, A.; Wang, G.; Chen, X.; Hopkins, W.; Cong, R.; Miller, J.; Urge, L.; Tarczy-Hornoch, K.; Loo, J. A.; Dooley, D. J.; Nadasdi, L.; Tsien, R. W.; Lemos, J.; Miljanich, G. Selective peptide antagonist of the class E calcium channel from the venom of the tarantula Hysterocrates gigas. Biochemistry, 1998, 37 (44), 15353-15362.
61. Tottene, A.; Volsen, S.; Pietrobon, D. Alpha(1E) subunits form the pore of three cerebellar R-type calcium channels with different pharmacological and permeation properties. J. Neurosci., 2000, 20 (1), 171-178.
62. Cassola, A. C.; Jaffe, H.; Fales, H. M.; Castro Afeche, S.; Magnoli, F.; Cipolla-Neto, J. Omega-phonetoxin-IIA: a calcium channel blocker from the spider phoneutria nigriventer. Pflugers Arch., 1998, 436 (4), 545-552.
63. Dos Santos, R. G.; Van Renterghem, C.; Martin-Moutot, N.; Mansuelle, P.; Cordeiro, M. N.; Diniz, C. R.; Mori, Y.; de Lima, M. E.; Seagar, M. Phoneutria nigriventer omega-phonetoxin IIA blocks the Cav2 family of calcium channels and interacts with omega-conotoxin-binding sites. J. Biol. Chem., 2002, 277 (16), 13856-13862.
64. Leao, R. M.; Cruz, J. S.; Diniz, C. R.; Cordeiro, M. N.; Beirao, P. S. Inhibition of neuronal high-voltage activated calcium channels by the omega-phoneutria nigriventer Tx3-3 peptide toxin. Neuropharmacology, 2000, 39 (10), 1756-17567.
65. Vieira, L. B.; Kushmerick, C.; Hildebrand, M. E.; Garcia, E.; Stea, A.; Cordeiro, M. N.; Richardson, M.; Gomez, M. V.; Snutch, T. P. Inhibition of high voltage-activated calcium channels by spider toxin PnTx3-6. J. Pharmacol. Exp. Ther., 2005, 314 (3), 1370-1377.
66. Becker, S.; Terlau, H. Toxins from cone snails: properties, applications and biotechnological production. Appl. Microbiol. Biotechnol., 2008, 79 (1), 1-9.
67. Rauck, R. L.; Wallace, M. S.; Burton, A. W.; Kapural, L.; North, J. M. Intrathecal ziconotide for neuropathic pain: a review. Pain Pract., 2009, 9 (5), 327-337.
68. Williams, J. A.; Day, M.; Heavner, J. E. Ziconotide: an update and review. Expert Opin. Pharmacother., 2008, 9 (9), 1575-1583.
69. Staats, P. S.; Yearwood, T.; Charapata, S. G.; Presley, R. W.; Wallace, M. S.; Byas-Smith, M.; Fisher, R.; Bryce, D. A.; Mangieri, E. A.; Luther, R. R.; Mayo, M.; McGuire, D.; Ellis, D. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. JAMA, 2004, 291 (1), 63-70.
70. Wermeling, D.; Drass, M.; Ellis, D.; Mayo, M.; McGuire, D.; O'Connell, D.; Hale, V.; Chao, S. Pharmacokinetics and pharmacodynamics of intrathecal ziconotide in chronic pain patients. J. Clin. Pharmacol., 2003, 43 (6), 624-636.
71. Wallace, M. S.; Kosek, P. S.; Staats, P.; Fisher, R.; Schultz, D. M.; Leong, M. Phase II, open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of ziconotide in patients receiving intrathecal morphine for severe chronic pain. Pain Med., 2008, 9 (3), 271-281.
72. Penn, R. D.; Paice, J. A. Adverse effects associated with the intrathecal administration of ziconotide. Pain, 2000, 85 (1-2), 291-296.
73. Clark, R. J.; Fischer, H.; Dempster, L.; Daly, N. L.; Rosengren, K. J.; Nevin, S. T.; Meunier, F. A.; Adams, D. J.; Craik, D. J. Engineering stable peptide toxins by means of backbone cyclization: stabilization of the alpha-conotoxin MII. Proc. Natl. Acad. Sci. USA, 2005, 102 (39), 13767-13772.
74. Berecki, G.; Motin, L.; Haythornthwaite, A.; Vink, S.; Bansal, P.; Drinkwater, R.; Wang, C. I.; Moretta, M.; Lewis, R. J.; Alewood, P. F.; Christie, M. J.; Adams, D. J. Analgesic (omega)-conotoxins CVIE and CVIF selectively and voltage-dependently block recombinant and native N-type calcium channels. Mol. Pharmacol., 2010,77 (2), 139-148.
75. Scott, D. A.; Wright, C. E.; Angus, J. A. Actions of intrathecal omega-conotoxins CVID, GVIA, MVIIA, and morphine in acute and neuropathic pain in the rat. Eur. J. Pharmacol., 2002, 451 (3), 279-286.
76. Gadjanski, I.; Boretius, S.; Williams, S. K.; Lingor, P.; Knoferle, J.; Sattler, M. B.; Fairless, R.; Hochmeister, S.; Suhs, K. W.; Michaelis, T.; Frahm, J.; Storch, M. K.; Bahr, M.; Diem, R. Role of n-type voltage-dependent calcium channels in autoimmune optic neuritis. Ann. Neurol., 2009, 66 (1), 81-93.
77. Duggan, P. J.; Lewis, R. J.; Phei Lok, Y.; Lumsden, N. G.; Tuck, K. L.; Yang, A. Low molecular weight non-peptide mimics of omega-conotoxin GVIA. Bioorg. Med. Chem. Lett., 2009, 19 (10), 2763-2765.
78. Urban, M. O.; Ren, K.; Sablad, M.; Park, K. T. Medullary N-type and P/Q-type calcium channels contribute to neuropathy-induced allodynia. Neuroreport, 2005, 16 (6), 563-566.
79. Jackson, H. C.; Scheideler, M. A. Behavioural and anticonvulsant effects of Ca2+ channel toxins in DBA/2 mice. Psychopharmacology (Berl), 1996, 126 (1), 85-90.
80. Matthews, E. A.; Bee, L. A.; Stephens, G. J.; Dickenson, A. H. The Cav2.3 calcium channel antagonist SNX-482 reduces dorsal horn neuronal responses in a rat model of chronic neuropathic pain. Eur. J. Neurosci., 2007, 25 (12), 3561-3569.
81. Escayg, A.; MacDonald, B. T.; Meisler, M. H.; Baulac, S.; Huberfeld, G.; An-Gourfinkel, I.; Brice, A.; LeGuern, E.; Moulard, B.; Chaigne, D.; Buresi, C.; Malafosse, A. Mutations of SCN1A, encoding a neuronal sodium channel, in two families with GEFS+2. Nat. Genet., 2000, 24 (4), 343-345.
82. Wallace, R. H.; Hodgson, B. L.; Grinton, B. E.; Gardiner, R. M.; Robinson, R.; Rodriguez-Casero, V.; Sadleir, L.; Morgan, J.; Harkin, L. A.; Dibbens, L. M.; Yamamoto, T.; Andermann, E.; Mulley, J. C.; Berkovic, S. F.; Scheffer, I. E. Sodium channel alpha1-subunit mutations in severe myoclonic epilepsy of infancy and infantile spasms. Neurology, 2003, 61 (6), 765-769.
83. Heron, S. E.; Crossland, K. M.; Andermann, E.; Phillips, H. A.; Hall, A. J.; Bleasel, A.; Shevell, M.; Mercho, S.; Seni, M. H.; Guiot, M. C.; Mulley, J. C.; Berkovic, S. F.; Scheffer, I. E. Sodiumchannel defects in benign familial neonatal-infantile seizures. Lancet, 2002, 360 (9336), 851-852.
84. Lehmann-Horn, F.; Jurkat-Rott, K. Voltage-gated ion channels and hereditary disease. Physiol. Rev., 1999, 79 (4), 1317-1372.
85. Ptacek, L. J.; George, A. L., Jr.; Griggs, R. C.; Tawil, R.; Kallen, R. G.; Barchi, R. L.; Robertson, M.; Leppert, M. F. Identification of a mutation in the gene causing hyperkalemic periodic paralysis. Cell, 1991, 67 (5), 1021-1027.
86. Chen, Q.; Kirsch, G. E.; Zhang, D.; Brugada, R.; Brugada, J.; Brugada, P.; Potenza, D.; Moya, A.; Borggrefe, M.; Breithardt, G.; Ortiz-Lopez, R.; Wang, Z.; Antzelevitch, C.; O'Brien, R. E.; Schulze-Bahr, E.; Keating, M. T.; Towbin, J. A.; Wang, Q. Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature, 1998, 392 (6673), 293-296.
87. Wang, Q.; Shen, J.; Splawski, I.; Atkinson, D.; Li, Z.; Robinson, J. L.; Moss, A. J.; Towbin, J. A.; Keating, M. T. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell, 1995, 80 (5), 805-811.
88. Schott, J. J.; Alshinawi, C.; Kyndt, F.; Probst, V.; Hoorntje, T. M.; Hulsbeek, M.; Wilde, A. A.; Escande, D.; Mannens, M. M.; le Marec, H. Cardiac conduction defects associate with mutations in SCN5A. Nat. Genet., 1999, 23 (1), 20-21.
89. Kohrman, D. C.; Smith, M. R.; Goldin, A. L.; Harris, J.; Meisler, M. H. A missense mutation in the sodium channel Scn8a is responsible for cerebellar ataxia in the mouse mutant jolting. J. Neurosci., 1996, 16 (19), 5993-5999.
90. Yang, Y.; Wang, Y.; Li, S.; Xu, Z.; Li, H.; Ma, L.; Fan, J.; Bu, D.; Liu, B.; Fan, Z.; Wu, G.; Jin, J.; Ding, B.; Zhu, X.; Shen, Y. Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia. J. Med. Genet., 2004, 41 (3), 171-174.
91. Cox, J. J.; Reimann, F.; Nicholas, A. K.; Thornton, G.; Roberts, E.; Springell, K.; Karbani, G.; Jafri, H.; Mannan, J.; Raashid, Y.; Al-Gazali, L.; Hamamy, H.; Valente, E. M.; Gorman, S.; Williams, R.; McHale, D. P.; Wood, J. N.; Gribble, F. M.; Woods, C. G. An SCN9A channelopathy causes congenital inability to experience pain. Nature, 2006, 444 (7121), 894-898.
92. Fertleman, C. R.; Baker, M. D.; Parker, K. A.; Moffatt, S.; Elmslie, F. V.; Abrahamsen, B.; Ostman, J.; Klugbauer, N.; Wood, J. N.; Gardiner, R. M.; Rees, M. SCN9A mutations in paroxysmal extreme pain disorder: allelic variants underlie distinct channel defects and phenotypes. Neuron, 2006, 52 (5), 767-774.
93. McClatchey, A. I.; van den Bergh, P.; Pericak-Vance, M. A.; Raskind, W.; Verellen, C.; McKenna-Yasek, D.; Rao, K.; Haines, J. L.; Bird, T.; Brown, R. H., Jr. Temperature-sensitive mutations in the III-IV cytoplasmic loop region of the skeletal muscle sodium channel gene in paramyotonia congenita. Cell, 1992, 68 (4), 769-774.
94. Heine, R.; Pika, U.; Lehmann-Horn, F. A novel SCN4A mutation causing myotonia aggravated by cold and potassium. Hum. Mol. Genet. 1993, 2 (9), 1349-1353.
95. Onkal, R.; Mattis, J. H.; Fraser, S. P.; Diss, J. K.; Shao, D.; Okuse, K.; Djamgoz, M. B. Alternative splicing of Nav1.5: an electrophysiological comparison of 'neonatal' and 'adult' isoforms and critical involvement of a lysine residue. J. Cell. Physiol., 2008, 216 (3), 716-726.
96. Gillet, L.; Roger, S.; Besson, P.; Lecaille, F.; Gore, J.; Bougnoux, P.; Lalmanach, G.; le Guennec, J. Y. Voltage-gated Sodium Channel Activity Promotes Cysteine Cathepsin-dependent Invasiveness and Colony Growth of Human Cancer Cells. J. Biol. Chem., 2009, 284 (13), 8680-8691.
97. Brackenbury, W. J.; Chioni, A. M.; Diss, J. K.; Djamgoz, M. B. The neonatal splice variant of Nav1.5 potentiates in vitro invasive behaviour of MDA-MB-231 human breast cancer cells. Breast Cancer Res. Treat., 2007, 101 (2), 149-160.
98. Onkal, R.; Djamgoz, M. B. Molecular pharmacology of voltagegated sodium channel expression in metastatic disease: clinical potential of neonatal Nav1.5 in breast cancer. Eur. J. Pharmacol., 2009, 625 (1-3), 206-219.
99. Amaya, F.; Wang, H.; Costigan, M.; Allchorne, A. J.; Hatcher, J. P.; Egerton, J.; Stean, T.; Morisset, V.; Grose, D.; Gunthorpe, M. J.; Chessell, I. P.; Tate, S.; Green, P. J.; Woolf, C. J. The voltagegated sodium channel Na(v)1.9 is an effector of peripheral inflammatory pain hypersensitivity. J. Neurosci., 2006, 26 (50), 12852-12860.
100. Priest, B. T.; Murphy, B. A.; Lindia, J. A.; Diaz, C.; Abbadie, C.; Ritter, A. M.; Liberator, P.; Iyer, L. M.; Kash, S. F.; Kohler, M. G.; Kaczorowski, G. J.; MacIntyre, D. E.; Martin, W. J. Contribution of the tetrodotoxin-resistant voltage-gated sodium channel NaV1.9 to sensory transmission and nociceptive behavior. Proc. Natl. Acad. Sci. USA, 2005, 102 (26), 9382-9387.
101. Dib-Hajj, S. D.; Binshtok, A. M.; Cummins, T. R.; Jarvis, M. F.; Samad, T.; Zimmermann, K. Voltage-gated sodium channels in pain states: role in pathophysiology and targets for treatment. Brain Res. Rev., 2009, 60 (1), 65-83.
102. Priest, B. T.; Kaczorowski, G. J. Subtype-selective sodium channel blockers promise a new era of pain research. Proc. Natl. Acad. Sci. USA, 2007, 104 (20), 8205-8206.
103. Oliveira, J. S.; Redaelli, E.; Zaharenko, A. J.; Cassulini, R. R.; Konno, K.; Pimenta, D. C.; Freitas, J. C.; Clare, J. J.; Wanke, E. Binding specificity of sea anemone toxins to Nav 1.1-1.6 sodium channels: unexpected contributions from differences in the IV/S3-S4 outer loop. J. Biol. Chem., 2004, 279 (32), 33323-33335.
104. Chahine, M.; Plante, E.; Kallen, R. G. Sea anemone toxin (ATX II) modulation of heart and skeletal muscle sodium channel alphasubunits expressed in tsA201 cells. J. Membr. Biol., 1996, 152 (1), 39-48.
105. Smith, R. D.; Goldin, A. L. Functional analysis of the rat I sodium channel in xenopus oocytes. J. Neurosci., 1998, 18 (3), 811-820.
106. Bosmans, F.; Maertens, C.; Verdonck, F.; Tytgat, J. The poison Dart frog's batrachotoxin modulates Nav1.8. FEBS Lett., 2004, 577 (1-2), 245-248.
107. Linford, N. J.; Cantrell, A. R.; Qu, Y.; Scheuer, T.; Catterall, W. A. Interaction of batrachotoxin with the local anesthetic receptor site in transmembrane segment IVS6 of the voltage-gated sodium channel. Proc. Natl. Acad. Sci. USA, 1998, 95 (23), 13947-13952.
108. Sheldon, R. S.; Cannon, N. J.; Duff, H. J. Binding of [3H]batrachotoxinin A benzoate to specific sites on rat cardiac sodium channels. Mol. Pharmacol., 1986, 30 (6), 617-623.
109. Wang, S. Y.; Wang, G. K. Point mutations in segment I-S6 render voltage-gated Na+ channels resistant to batrachotoxin. Proc. Natl. Acad. Sci. USA, 1998, 95 (5), 2653-2658.
110. Cestele, S.; Qu, Y.; Rogers, J. C.; Rochat, H.; Scheuer, T.; Catterall, W. A. Voltage sensor-trapping: enhanced activation of sodium channels by beta-scorpion toxin bound to the S3-S4 loop in domain II. Neuron, 1998, 21 (4), 919-931.
111. Fiedler, B.; Zhang, M. M.; Buczek, O.; Azam, L.; Bulaj, G.; Norton, R. S.; Olivera, B. M.; Yoshikami, D. Specificity, affinity and efficacy of iota-conotoxin RXIA, an agonist of voltage-gated sodium channels Na(V)1.2, 1.6 and 1.7. Biochem. Pharmacol., 2008, 75 (12), 2334-2344.
112. Rogers, J. C.; Qu, Y.; Tanada, T. N.; Scheuer, T.; Catterall, W. A. Molecular determinants of high affinity binding of alpha-scorpion toxin and sea anemone toxin in the S3-S4 extracellular loop in domain IV of the Na+ channel alpha subunit. J. Biol. Chem., 1996, 271 (27), 15950-15962.
113. Sudarslal, S.; Majumdar, S.; Ramasamy, P.; Dhawan, R.; Pal, P. P.; Ramaswami, M.; Lala, A. K.; Sikdar, S. K.; Sarma, S. P.; Krishnan, K. S.; Balaram, P. Sodium channel modulating activity in a deltaconotoxin from an Indian marine snail. FEBS Lett., 2003, 553 (1-2), 209-212.
114. Bricelj, V. M.; Connell, L.; Konoki, K.; Macquarrie, S. P.; Scheuer, T.; Catterall, W. A.; Trainer, V. L. Sodium channel mutation leading to saxitoxin resistance in clams increases risk of PSP. Nature, 2005, 434 (7034), 763-767.
115. Zhang, M. M.; Green, B. R.; Catlin, P.; Fiedler, B.; Azam, L.; Chadwick, A.; Terlau, H.; McArthur, J. R.; French, R. J.; Gulyas, J.; Rivier, J. E.; Smith, B. J.; Norton, R. S.; Olivera, B. M.; Yoshikami, D.; Bulaj, G. Structure/function characterization of micro-conotoxin KIIIA, an analgesic, nearly irreversible blocker of mammalian neuronal sodium channels. J. Biol. Chem., 2007, 282 (42), 30699-30706.
116. Schroeder, C. I.; Ekberg, J.; Nielsen, K. J.; Adams, D.; Loughnan, M. L.; Thomas, L.; Adams, D. J.; Alewood, P. F.; Lewis, R. J. Neuronally micro-conotoxins from Conus striatus utilize an alphahelical motif to target mammalian sodium channels. J. Biol. Chem., 2008, 283 (31), 21621-21628.
117. Yao, S.; Zhang, M. M.; Yoshikami, D.; Azam, L.; Olivera, B. M.; Bulaj, G.; Norton, R. S. Structure, dynamics, and selectivity of the sodium channel blocker mu-conotoxin SIIIA. Biochemistry, 2008, 47 (41), 10940-10949.
118. Joho, R. H.; Moorman, J. R.; VanDongen, A. M.; Kirsch, G. E.; Silberberg, H.; Schuster, G.; Brown, A. M. Toxin and kinetic profile of rat brain type III sodium channels expressed in Xenopus oocytes. Brain Res. Mol. Brain Res., 1990, 7 (2), 105-113.
119. Chen, Y. H.; Dale, T. J.; Romanos, M. A.; Whitaker, W. R.; Xie, X. M.; Clare, J. J. Cloning, distribution and functional analysis of the type III sodium channel from human brain. Eur. J. Neurosci., 2000, 12 (12), 4281-1289.
120. Marcotte, P.; Chen, L. Q.; Kallen, R. G.; Chahine, M. Effects of Tityus serrulatus scorpion toxin gamma on voltage-gated Na+ channels. Circ. Res., 1997, 80 (3), 363-369.
121. Choudhary, G.; Aliste, M. P.; Tieleman, D. P.; French, R. J.; Dudley, S. C., Jr., Docking of mu-conotoxin GIIIA in the sodium channel outer vestibule. Channels (Austin), 2007, 1 (5), 344-352.
122. Cruz, L. J.; Gray, W. R.; Olivera, B. M.; Zeikus, R. D.; Kerr, L.; Yoshikami, D.; Moczydlowski, E. Conus geographus toxins that discriminate between neuronal and muscle sodium channels. J. Biol. Chem., 1985, 260 (16), 9280-9288.
123. Lewis, R. J.; Schroeder, C. I.; Ekberg, J.; Nielsen, K. J.; Loughnan, M.; Thomas, L.; Adams, D. A.; Drinkwater, R.; Adams, D. J.; Alewood, P. F. Isolation and structure-activity of mu-conotoxin TIIIA, a potent inhibitor of tetrodotoxin-sensitive voltage-gated sodium channels. Mol. Pharmacol., 2007, 71 (3), 676-685.
124. Safo, P.; Rosenbaum, T.; Shcherbatko, A.; Choi, D. Y.; Han, E.; Toledo-Aral, J. J.; Olivera, B. M.; Brehm, P.; Mandel, G. Distinction among neuronal subtypes of voltage-activated sodium channels by mu-conotoxin PIIIA. J. Neurosci., 2000, 20 (1), 76-80.
125. Shon, K. J.; Olivera, B. M.; Watkins, M.; Jacobsen, R. B.; Gray, W. R.; Floresca, C. Z.; Cruz, L. J.; Hillyard, D. R.; Brink, A.; Terlau, H.; Yoshikami, D. Mu-Conotoxin PIIIA, a new peptide for discriminating among tetrodotoxin-sensitive Na channel subtypes. J. Neurosci., 1998, 18 (12), 4473-4481.
126. Chahine, M.; Bennett, P. B.; George, A. L., Jr.; Horn, R. Functional expression and properties of the human skeletal muscle sodium channel. Pflugers Arch., 1994, 427 (1-2), 136-142.
127. Walewska, A.; Skalicky, J. J.; Davis, D. R.; Zhang, M. M.; Lopez- Vera, E.; Watkins, M.; Han, T. S.; Yoshikami, D.; Olivera, B. M.; Bulaj, G. NMR-based mapping of disulfide bridges in cysteine-rich peptides: application to the mu-conotoxin SxIIIA. J. Am. Chem. Soc., 2008, 130 (43), 14280-14286.
128. Cribbs, L. L.; Satin, J.; Fozzard, H. A.; Rogart, R. B. Functional expression of the rat heart I Na+ channel isoform. Demonstration of properties characteristic of native cardiac Na+ channels. FEBS Lett., 1990, 275 (1/2), 195-200.
129. Zeng, D.; Kyle, J. W.; Martin, R. L.; Ambler, K. S.; Hanck, D. A. Cardiac sodium channels expressed in a peripheral neurotumorderived cell line, RT4-B8. Am. J. Physiol., 1996, 270 (5 Pt 1), C1522-1531.
130. Schiavon, E.; Sacco, T.; Cassulini, R. R.; Gurrola, G.; Tempia, F.; Possani, L. D.; Wanke, E. Resurgent current and voltage sensor trapping enhanced activation by a beta-scorpion toxin solely in Nav1.6 channel. Significance in mice Purkinje neurons. J. Biol. Chem., 2006, 281 (29), 20326-20337.
131. Zhang, M.; Liu, X. S.; Diochot, S.; Lazdunski, M.; Tseng, G. N. APETx1 from sea anemone Anthopleura elegantissima is a gating modifier peptide toxin of the human ether-a-go-go- related potassium channel. Mol. Pharmacol., 2007, 72 (2), 259-268.
132. Maertens, C.; Cuypers, E.; Amininasab, M.; Jalali, A.; Vatanpour, H.; Tytgat, J. Potent modulation of the voltage-gated sodium channel Nav1.7 by OD1, a toxin from the scorpion Odonthobuthus doriae. Mol. Pharmacol., 2006, 70 (1), 405-414.
133. Klugbauer, N.; Lacinova, L.; Flockerzi, V.; Hofmann, F. Structure and functional expression of a new member of the tetrodotoxinsensitive voltage-activated sodium channel family from human neuroendocrine cells. EMBO J., 1995, 14 (6), 1084-1090.
134. Leipold, E.; DeBie, H.; Zorn, S.; Borges, A.; Olivera, B. M.; Terlau, H.; Heinemann, S. H. MuO conotoxins inhibit NaV channels by interfering with their voltage sensors in domain-2. Channels (Austin), 2007, 1 (4), 253-262.
135. Ekberg, J.; Jayamanne, A.; Vaughan, C. W.; Aslan, S.; Thomas, L.; Mould, J.; Drinkwater, R.; Baker, M. D.; Abrahamsen, B.; Wood, J. N.; Adams, D. J.; Christie, M. J.; Lewis, R. J. MuO-conotoxin MrVIB selectively blocks Nav1.8 sensory neuron specific sodium channels and chronic pain behavior without motor deficits. Proc. Natl. Acad. Sci. USA, 2006, 103 (45), 17030-17035.
136. Akopian, A. N.; Sivilotti, L.; Wood, J. N. A tetrodotoxin-resistant voltage-gated sodium channel expressed by sensory neurons. Nature, 1996, 379 (6562), 257-262.
137. Cummins, T. R.; Dib-Hajj, S. D.; Black, J. A.; Akopian, A. N.; Wood, J. N.; Waxman, S. G. A novel persistent tetrodotoxinresistant sodium current in SNS-null and wild-type small primary sensory neurons. J. Neurosci., 1999, 19 (24), RC43.
138. Wang, C. Z.; Zhang, H.; Jiang, H.; Lu, W.; Zhao, Z. Q.; Chi, C. W. A novel conotoxin from Conus striatus, mu-SIIIA, selectively blocking rat tetrodotoxin-resistant sodium channels. Toxicon, 2006, 47 (1), 122-132.
139. Couraud, F.; Jover, E.; Dubois, J. M.; Rochat, H. Two types of scorpion receptor sites, one related to the activation, the other to the inactivation of the action potential sodium channel. Toxicon, 1982, 20 (1), 9-16.
140. Guan, R. J.; He, X. L.; Wang, M.; Ye, X.; Li, G. P.; Wang, D. C. Purification, crystallization and initial structural solution of a new alpha-like toxin with cardiac toxicity from scorpion Buthus martensii Karsch. Protein Pept. Lett., 2002, 9 (5), 441-449.
141. Wang, C. Y.; Tan, Z. Y.; Chen, B.; Zhao, Z. Q.; Ji, Y. H. Antihyperalgesia effect of BmK IT2, a depressant insect-selective scorpion toxin in rat by peripheral administration. Brain Res. Bull., 2000, 53 (3), 335-358.
142. Ji, Y. H.; Mansuelle, P.; Xu, K.; Granier, C.; Kopeyan, C.; Terakawa, S.; Rochat, H. Amino acid sequence of an excitatory insect-selective toxin (BmK IT) from venom of the scorpion Buthus martensi Karsch. Sci. China. B., 1994, 37 (1), 42-49.
143. Tan, Z. Y.; Xiao, H.; Mao, X.; Wang, C. Y.; Zhao, Z. Q.; Ji, Y. H., The inhibitory effects of BmK IT2, a scorpion neurotoxin on rat nociceptive flexion reflex and a possible mechanism for modulating voltage-gated Na(+) channels. Neuropharmacology, 2001, 40 (3), 352-357.
144. Biggin, P. C.; Roosild, T.; Choe, S. Potassium channel structure: domain by domain. Curr. Opin. Struct. Biol., 2000, 10 (4), 456-461.
145. Gogas, K. R. Glutamate-based therapeutic approaches: NR2B receptor antagonists. Curr. Opin. Pharmacol., 2006, 6 (1), 68-74.
146. Sansom, M. S.; Shrivastava, I. H.; Bright, J. N.; Tate, J.; Capener, C. E.; Biggin, P. C. Potassium channels: structures, models, simulations. Biochim. Biophys. Acta, 2002, 1565 (2), 294-307.
147. Wang, C. X.; Shuaib, A. NMDA/NR2B selective antagonists in the treatment of ischemic brain injury. Curr. Drug Targets CNS Neurol. Disord., 2005, 4 (2), 143-151.
148. Goldstein, S. A.; Bayliss, D. A.; Kim, D.; Lesage, F.; Plant, L. D.; Rajan, S. International Union of Pharmacology. LV. Nomenclature and molecular relationships of two-P potassium channels. Pharmacol. Rev., 2005, 57 (4), 527-540.
149. Gutman, G. A.; Chandy, K. G.; Adelman, J. P.; Aiyar, J.; Bayliss, D. A.; Clapham, D. E.; Covarriubias, M.; Desir, G. V.; Furuichi, K.; Ganetzky, B.; Garcia, M. L.; Grissmer, S.; Jan, L. Y.; Karschin, A.; Kim, D.; Kuperschmidt, S.; Kurachi, Y.; Lazdunski, M.; Lesage, F.; Lester, H. A.; McKinnon, D.; Nichols, C. G.; O'Kelly, I.; Robbins, J.; Robertson, G. A.; Rudy, B.; Sanguinetti, M.; Seino, S.; Stuehmer, W.; Tamkun, M. M.; Vandenberg, C. A.; Wei, A.; Wulff, H.; Wymore, R. S. International Union of Pharmacology. XLI. Compendium of voltage-gated ion channels: potassium channels. Pharmacol. Rev., 2003, 55 (4), 583-586.
150. Gutman, G. A.; Chandy, K. G.; Grissmer, S.; Lazdunski, M.; McKinnon, D.; Pardo, L. A.; Robertson, G. A.; Rudy, B.; Sanguinetti, M. C.; Stuhmer, W.; Wang, X. International Union of Pharmacology. LIII. Nomenclature and molecular relationships of voltage-gated potassium channels. Pharmacol. Rev., 2005, 57 (4), 473-508.
151. Kubo, Y.; Adelman, J. P.; Clapham, D. E.; Jan, L. Y.; Karschin, A.; Kurachi, Y.; Lazdunski, M.; Nichols, C. G.; Seino, S.; Vandenberg, C. A. International Union of Pharmacology. LIV. Nomenclature and molecular relationships of inwardly rectifying potassium channels. Pharmacol. Rev., 2005, 57 (4), 509-526.
152. Wei, A. D.; Gutman, G. A.; Aldrich, R.; Chandy, K. G.; Grissmer, S.; Wulff, H. International Union of Pharmacology. LII. Nomenclature and molecular relationships of calcium-activated potassium channels. Pharmacol. Rev. 2005, 57 (4), 463-472.
153. Vacher, H.; Mohapatra, D. P.; Trimmer, J. S. Localization and targeting of voltage-dependent ion channels in mammalian central neurons. Physiol. Rev., 2008, 88 (4), 1407-1447.
154. Schwab, A.; Hanley, P.; Fabian, A.; Stock, C. Potassium channels keep mobile cells on the go. Physiology (Bethesda), 2008, 23, 212-220.
155. Boyd, A. E., 3rd. The role of ion channels in insulin secretion. J. Cell. Biochem., 1992, 48 (3), 235-241.
156. Browne, D. L.; Gancher, S. T.; Nutt, J. G.; Brunt, E. R.; Smith, E. A.; Kramer, P.; Litt, M. Episodic ataxia/myokymia syndrome is associated with point mutations in the human potassium channel gene, KCNA1. Nat. Genet., 1994, 8 (2), 136-140.
157. Singh, B.; Ogiwara, I.; Kaneda, M.; Tokonami, N.; Mazaki, E.; Baba, K.; Matsuda, K.; Inoue, Y.; Yamakawa, K. A Kv4.2 truncation mutation in a patient with temporal lobe epilepsy. Neurobiol. Dis., 2006, 24 (2), 245-253.
158. Abbott, G. W.; Butler, M. H.; Bendahhou, S.; Dalakas, M. C.; Ptacek, L. J.; Goldstein, S. A. MiRP2 forms potassium channels in skeletal muscle with Kv3.4 and is associated with periodic paralysis. Cell, 2001, 104 (2), 217-231.
159. Figueroa, K. P.; Minassian, N. A.; Stevanin, G.; Waters, M.; Garibyan, V.; Forlani, S.; Strzelczyk, A.; Burk, K.; Brice, A.; Durr, A.; Papazian, D. M.; Pulst, S. M. KCNC3: phenotype, mutations, channel biophysics-a study of 260 familial ataxia patients. Hum. Mutat., 2010, 31 (2), 191-196.
160. Waters, M. F.; Minassian, N. A.; Stevanin, G.; Figueroa, K. P.; Bannister, J. P.; Nolte, D.; Mock, A. F.; Evidente, V. G.; Fee, D. B.; Muller, U.; Durr, A.; Brice, A.; Papazian, D. M.; Pulst, S. M. Mutations in voltage-gated potassium channel KCNC3 cause degenerative and developmental central nervous system phenotypes. Nat. Genet., 2006, 38 (4), 447-451.
161. Bellocq, C.; van Ginneken, A. C.; Bezzina, C. R.; Alders, M.; Escande, D.; Mannens, M. M.; Baro, I.; Wilde, A. A. Mutation in the KCNQ1 gene leading to the short QT-interval syndrome. Circulation, 2004, 109 (20), 2394-2397.
162. Dedek, K.; Kunath, B.; Kananura, C.; Reuner, U.; Jentsch, T. J.; Steinlein, O. K. Myokymia and neonatal epilepsy caused by a mutation in the voltage sensor of the KCNQ2 K+ channel. Proc. Natl. Acad. Sci. USA, 2001, 98 (21), 12272-12277.
163. Biervert, C.; Schroeder, B. C.; Kubisch, C.; Berkovic, S. F.; Propping, P.; Jentsch, T. J.; Steinlein, O. K. A potassium channel mutation in neonatal human epilepsy. Science, 1998, 279 (5349), 403-406.
164. Singh, N. A.; Charlier, C.; Stauffer, D.; DuPont, B. R.; Leach, R. J.; Melis, R.; Ronen, G. M.; Bjerre, I.; Quattlebaum, T.; Murphy, J. V.; McHarg, M. L.; Gagnon, D.; Rosales, T. O.; Peiffer, A.; Anderson, V. E.; Leppert, M. A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns. Nat. Genet., 1998, 18 (1), 25-29.
165. Schroeder, B. C.; Kubisch, C.; Stein, V.; Jentsch, T. J., Moderate loss of function of cyclic-AMP-modulated KCNQ2/KCNQ3 K+ channels causes epilepsy. Nature, 1998, 396 (6712), 687-690.
166. Kubisch, C.; Schroeder, B. C.; Friedrich, T.; Lutjohann, B.; El- Amraoui, A.; Marlin, S.; Petit, C.; Jentsch, T. J. KCNQ4, a novel potassium channel expressed in sensory outer hair cells, is mutated in dominant deafness. Cell, 1999, 96 (3), 437-446.
167. Simon, D. B.; Karet, F. E.; Rodriguez-Soriano, J.; Hamdan, J. H.; DiPietro, A.; Trachtman, H.; Sanjad, S. A.; Lifton, R. P. Genetic heterogeneity of Bartter's syndrome revealed by mutations in the K+ channel, ROMK. Nat. Genet., 1996, 14 (2), 152-156.
168. Plaster, N. M.; Tawil, R.; Tristani-Firouzi, M.; Canun, S.; Bendahhou, S.; Tsunoda, A.; Donaldson, M. R.; Iannaccone, S. T.; Brunt, E.; Barohn, R.; Clark, J.; Deymeer, F.; George, A. L., Jr.; Fish, F. A.; Hahn, A.; Nitu, A.; Ozdemir, C.; Serdaroglu, P.; Subramony, S. H.; Wolfe, G.; Fu, Y. H.; Ptacek, L. J. Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen's syndrome. Cell, 2001, 105 (4), 511-519.
169. Thomas, P.; Ye, Y.; Lightner, E. Mutation of the pancreatic islet inward rectifier Kir6.2 also leads to familial persistent hyperinsulinemic hypoglycemia of infancy. Hum. Mol. Genet., 1996, 5 (11), 1809-1812.
170. Gloyn, A. L.; Pearson, E. R.; Antcliff, J. F.; Proks, P.; Bruining, G. J.; Slingerland, A. S.; Howard, N.; Srinivasan, S.; Silva, J. M.; Molnes, J.; Edghill, E. L.; Frayling, T. M.; Temple, I. K.; Mackay, D.; Shield, J. P.; Sumnik, Z.; van Rhijn, A.; Wales, J. K.; Clark, P.; Gorman, S.; Aisenberg, J.; Ellard, S.; Njolstad, P. R.; Ashcroft, F. M.; Hattersley, A. T. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N. Engl. J. Med., 2004, 350 (18), 1838-1849.
171. Beeton, C.; Pennington, M. W.; Wulff, H.; Singh, S.; Nugent, D.; Crossley, G.; Khaytin, I.; Calabresi, P. A.; Chen, C. Y.; Gutman, G. A.; Chandy, K. G. Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases. Mol. Pharmacol., 2005, 67 (4), 1369-1381.
172. Coghlan, M. J.; Carroll, W. A.; Gopalakrishnan, M. Recent developments in the biology and medicinal chemistry of potassium channel modulators: update from a decade of progress. J. Med. Chem., 2001, 44 (11), 1627-1653.
173. Wickenden, A. K+ channels as therapeutic drug targets. Pharmacol. Ther., 2002, 94 (1/2), 157-182.
174. Wulff, H.; Castle, N. A.; Pardo, L. A. Voltage-gated potassium channels as therapeutic targets. Nat. Rev. Drug Discov., 2009, 8 (12), 982-1001.
175. Grissmer, S.; Nguyen, A. N.; Aiyar, J.; Hanson, D. C.; Mather, R. J.; Gutman, G. A.; Karmilowicz, M. J.; Auperin, D. D.; Chandy, K. G. Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines. Mol. Pharmacol., 1994, 45 (6), 1227-1234.
176. Robertson, B.; Owen, D.; Stow, J.; Butler, C.; Newland, C. Novel effects of dendrotoxin homologues on subtypes of mammalian Kv1 potassium channels expressed in Xenopus oocytes. FEBS Lett., 1996, 383 (1-2), 26-30.
177. Koschak, A.; Bugianesi, R. M.; Mitterdorfer, J.; Kaczorowski, G. J.; Garcia, M. L.; Knaus, H. G. Subunit composition of brain voltage-gated potassium channels determined by hongotoxin-1, a novel peptide derived from Centruroides limbatus venom. J. Biol. Chem., 1998, 273 (5), 2639-2644.
178. Garcia-Calvo, M.; Leonard, R. J.; Novick, J.; Stevens, S. P.; Schmalhofer, W.; Kaczorowski, G. J.; Garcia, M. L. Purification, characterization, and biosynthesis of margatoxin, a component of Centruroides margaritatus venom that selectively inhibits voltagedependent potassium channels. J. Biol. Chem., 1993, 268 (25), 18866-18874.
179. Kalman, K.; Pennington, M. W.; Lanigan, M. D.; Nguyen, A.; Rauer, H.; Mahnir, V.; Paschetto, K.; Kem, W. R.; Grissmer, S.; Gutman, G. A.; Christian, E. P.; Cahalan, M. D.; Norton, R. S.; Chandy, K. G. ShK-Dap22, a potent Kv1.3-specific immunosuppressive polypeptide. J. Biol. Chem., 1998, 273 (49), 32697-707.
180. Alessandri-Haber, N.; Lecoq, A.; Gasparini, S.; Grangier- Macmath, G.; Jacquet, G.; Harvey, A. L.; de Medeiros, C.; Rowan, E. G.; Gola, M.; Menez, A.; Crest, M. Mapping the functional anatomy of BgK on Kv1.1, Kv1.2, and Kv1.3. Clues to design analogs with enhanced selectivity. J. Biol. Chem., 1999, 274 (50), 35653-35661.
181. Dudina, E. E.; Korolkova, Y. V.; Bocharova, N. E.; Koshelev, S. G.; Egorov, T. A.; Huys, I.; Tytgat, J.; Grishin, E. V. OsK2, a new selective inhibitor of Kv1.2 potassium channels purified from the venom of the scorpion Orthochirus scrobiculosus. Biochem. Biophys. Res. Commun., 2001, 286 (5), 841-847.
182. Rogowski, R. S.; Collins, J. H.; O'Neill, T. J.; Gustafson, T. A.; Werkman, T. R.; Rogawski, M. A.; Tenenholz, T. C.; Weber, D. J.; Blaustein, M. P. Three new toxins from the scorpion Pandinus imperator selectively block certain voltage-gated K+ channels. Mol. Pharmacol., 1996, 50 (5), 1167-1177.
183. Werkman, T. R.; Gustafson, T. A.; Rogowski, R. S.; Blaustein, M. P.; Rogawski, M. A. Tityustoxin-K alpha, a structurally novel and highly potent K+ channel peptide toxin, interacts with the alphadendrotoxin binding site on the cloned Kv1.2 K+ channel. Mol. Pharmacol., 1993, 44 (2), 430-436.
184. Cotton, J.; Crest, M.; Bouet, F.; Alessandri, N.; Gola, M.; Forest, E.; Karlsson, E.; Castaneda, O.; Harvey, A. L.; Vita, C.; Menez, A. A potassium-channel toxin from the sea anemone Bunodosoma granulifera, an inhibitor for Kv1 channels. Revision of the amino acid sequence, disulfide-bridge assignment, chemical synthesis, and biological activity. Eur. J. Biochem., 1997, 244 (1), 192-202.
185. Ferber, M.; Al-Sabi, A.; Stocker, M.; Olivera, B. M.; Terlau, H. Identification of a mammalian target of kappaM-conotoxin RIIIK. Toxicon, 2004, 43 (8), 915-21.
186. Ghanshani, S.; Wulff, H.; Miller, M. J.; Rohm, H.; Neben, A.; Gutman, G. A.; Cahalan, M. D.; Chandy, K. G. Up-regulation of the IKCa1 potassium channel during T-cell activation. Molecular mechanism and functional consequences. J. Biol. Chem., 2000, 275 (47), 37137-37149.
187. Aiyar, J.; Withka, J. M.; Rizzi, J. P.; Singleton, D. H.; Andrews, G. C.; Lin, W.; Boyd, J.; Hanson, D. C.; Simon, M.; Dethlefs, B. Topology of the pore-region of a K+ channel revealed by the NMR-derived structures of scorpion toxins. Neuron, 1995, 15 (5), 1169-1181.
188. Mouhat, S.; Teodorescu, G.; Homerick, D.; Visan, V.; Wulff, H.; Wu, Y.; Grissmer, S.; Darbon, H.; De Waard, M.; Sabatier, J. M. Pharmacological profiling of Orthochirus scrobiculosus toxin 1 analogs with a trimmed N-terminal domain. Mol. Pharmacol., 2006, 69 (1), 354-362.
189. Grupe, A.; Schroter, K. H.; Ruppersberg, J. P.; Stocker, M.; Drewes, T.; Beckh, S.; Pongs, O. Cloning and expression of a human voltage-gated potassium channel. A novel member of the RCK potassium channel family. EMBO J., 1990, 9 (6), 1749-1756.
190. Racape, J.; Lecoq, A.; Romi-Lebrun, R.; Liu, J.; Kohler, M.; Garcia, M. L.; Menez, A.; Gasparini, S. Characterization of a novel radiolabeled peptide selective for a subpopulation of voltage-gated potassium channels in mammalian brain. J. Biol. Chem., 2002, 277 (6), 3886-3893.
191. Imperial, J. S.; Bansal, P. S.; Alewood, P. F.; Daly, N. L.; Craik, D. J.; Sporning, A.; Terlau, H.; Lopez-Vera, E.; Bandyopadhyay, P. K.; Olivera, B. M. A novel conotoxin inhibitor of Kv1.6 channel and nAChR subtypes defines a new superfamily of conotoxins. Biochemistry, 2006, 45 (27), 8331-8840.
192. Lang, R.; Lee, G.; Liu, W.; Tian, S.; Rafi, H.; Orias, M.; Segal, A. S.; Desir, G. V. KCNA10: a novel ion channel functionally related to both voltage-gated potassium and CNG cation channels. Am. J. Physiol. Renal. Physiol. 2000, 278 (6), F1013-1021.
193. Swartz, K. J.; MacKinnon, R. An inhibitor of the Kv2.1 potassium channel isolated from the venom of a Chilean tarantula. Neuron, 1995, 15 (4), 941-949.
194. Albrecht, B.; Lorra, C.; Stocker, M.; Pongs, O. Cloning and characterization of a human delayed rectifier potassium channel gene. Receptors Channels, 1993, 1 (2), 99-110.
195. Liao, Z.; Yuan, C.; Peng, K.; Xiao, Y.; Liang, S. Solution structure of Jingzhaotoxin-III, a peptide toxin inhibiting both Nav1.5 and Kv2.1 channels. Toxicon, 2007, 50 (1), 135-143.
196. Escoubas, P.; De Weille, J. R.; Lecoq, A.; Diochot, S.; Waldmann, R.; Champigny, G.; Moinier, D.; Menez, A.; Lazdunski, M. Isolation of a tarantula toxin specific for a class of proton-gated Na+ channels. J. Biol. Chem., 2000, 275 (33), 25116-25121.
197. Yan, L.; Herrington, J.; Goldberg, E.; Dulski, P. M.; Bugianesi, R. M.; Slaughter, R. S.; Banerjee, P.; Brochu, R. M.; Priest, B. T.; Kaczorowski, G. J.; Rudy, B.; Garcia, M. L. Stichodactyla helianthus peptide, a pharmacological tool for studying Kv3.2 channels. Mol. Pharmacol., 2005, 67 (5), 1513-1521.
198. Diochot, S.; Schweitz, H.; Beress, L.; Lazdunski, M. Sea anemone peptides with a specific blocking activity against the fast inactivating potassium channel Kv3.4. J. Biol. Chem., 1998, 273 (12), 6744-6749.
199. Zarayskiy, V. V.; Balasubramanian, G.; Bondarenko, V. E.; Morales, M. J. Heteropoda toxin 2 is a gating modifier toxin specific for voltage-gated K+ channels of the Kv4 family. Toxicon, 2005, 45 (4), 431-442.
200. Sanguinetti, M. C.; Johnson, J. H.; Hammerland, L. G.; Kelbaugh, P. R.; Volkmann, R. A.; Saccomano, N. A.; Mueller, A. L. Heteropodatoxins: peptides isolated from spider venom that block Kv4.2 potassium channels. Mol. Pharmacol., 1997, 51 (3), 491-498.
201. Diochot, S.; Drici, M. D.; Moinier, D.; Fink, M.; Lazdunski, M. Effects of phrixotoxins on the Kv4 family of potassium channels and implications for the role of Ito1 in cardiac electrogenesis. Br. J. Pharmacol., 1999, 126 (1), 251-263.
202. Vacher, H.; Diochot, S.; Bougis, P. E.; Martin-Eauclaire, M. F.; Mourre, C. Kv4 channels sensitive to BmTX3 in rat nervous system: autoradiographic analysis of their distribution during brain ontogenesis. Eur. J. Neurosci., 2006, 24 (5), 1325-1340.
203. Wang, H.; Shi, H.; Zhang, L.; Pourrier, M.; Yang, B.; Nattel, S.; Wang, Z. Nicotine is a potent blocker of the cardiac A-type K(+) channels. Effects on cloned Kv4.3 channels and native transient outward current. Circulation, 2000, 102 (10), 1165-1171.
204. Castaneda, O.; Harvey, A. L. Discovery and characterization of cnidarian peptide toxins that affect neuronal potassium ion channels. Toxicon, 2009, 54 (8), 1119-1124.
205. Diochot, S.; Loret, E.; Bruhn, T.; Beress, L.; Lazdunski, M. APETx1, a new toxin from the sea anemone Anthopleura elegantissima, blocks voltage-gated human ether-a-go-go-related gene potassium channels. Mol. Pharmacol., 2003, 64 (1), 59-69.
206. Korolkova, Y. V.; Bocharov, E. V.; Angelo, K.; Maslennikov, I. V.; Grinenko, O. V.; Lipkin, A. V.; Nosyreva, E. D.; Pluzhnikov, K. A.; Olesen, S. P.; Arseniev, A. S.; Grishin, E. V. New binding site on common molecular scaffold provides HERG channel specificity of scorpion toxin BeKm-1. J. Biol. Chem., 2002, 277 (45), 43104-43109.
207. Redaelli, E.; Cassulini, R. R.; Silva, D. F.; Clement, H.; Schiavon, E.; Zamudio, F. Z.; Odell, G.; Arcangeli, A.; Clare, J. J.; Alagon, A.; de la Vega, R. C.; Possani, L. D.; Wanke, E. Target promiscuity and heterogeneous effects of tarantula venom peptides affecting Na+ and K+ ion channels. J. Biol. Chem., 2010, 285 (6), 4130-4142.
208. Shi, W.; Wymore, R. S.; Wang, H. S.; Pan, Z.; Cohen, I. S.; McKinnon, D.; Dixon, J. E. Identification of two nervous systemspecific members of the erg potassium channel gene family. J. Neurosci., 1997, 17 (24), 9423-9432.
209. Wanke, E.; Restano-Cassulini, R. Toxins interacting with ether-ago- go-related gene voltage-dependent potassium channels. Toxicon, 2007, 49 (2), 239-248.
210. Douglass, J.; Osborne, P. B.; Cai, Y. C.; Wilkinson, M.; Christie, M. J.; Adelman, J. P. Characterization and functional expression of a rat genomic DNA clone encoding a lymphocyte potassium channel. J. Immunol., 1990, 144 (12), 4841-4850.
211. Grissmer, S.; Dethlefs, B.; Wasmuth, J. J.; Goldin, A. L.; Gutman, G. A.; Cahalan, M. D.; Chandy, K. G. Expression and chromosomal localization of a lymphocyte K+ channel gene. Proc. Natl. Acad. Sci. USA, 1990, 87 (23), 9411-9415.
212. Helms, L. M.; Felix, J. P.; Bugianesi, R. M.; Garcia, M. L.; Stevens, S.; Leonard, R. J.; Knaus, H. G.; Koch, R.; Wanner, S. G.; Kaczorowski, G. J.; Slaughter, R. S. Margatoxin binds to a homomultimer of K(v)1.3 channels in Jurkat cells. Comparison with Kv1.3 expressed in CHO cells. Biochemistry, 1997, 36 (12), 3737-3744.
213. Cahalan, M. D.; Chandy, K. G. The functional network of ion channels in T lymphocytes. Immunol. Rev., 2009, 231 (1), 59-87.
214. Wulff, H.; Zhorov, B. S. K+ channel modulators for the treatment of neurological disorders and autoimmune diseases. Chem. Rev. 2008, 108 (5), 1744-1773.
215. Chandy, K. G.; Wulff, H.; Beeton, C.; Pennington, M.; Gutman, G. A.; Cahalan, M. D. K+ channels as targets for specific immunomodulation. Trends Pharmacol. Sci., 2004, 25 (5), 280-289.
216. Wulff, H.; Calabresi, P. A.; Allie, R.; Yun, S.; Pennington, M.; Beeton, C.; Chandy, K. G. The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS. J. Clin. Invest., 2003, 111 (11), 1703-1713.
217. Beeton, C.; Wulff, H.; Standifer, N. E.; Azam, P.; Mullen, K. M.; Pennington, M. W.; Kolski-Andreaco, A.; Wei, E.; Grino, A.; Counts, D. R.; Wang, P. H.; LeeHealey, C. J.; B, S. A.; Sankaranarayanan, A.; Homerick, D.; Roeck, W. W.; Tehranzadeh, J.; Stanhope, K. L.; Zimin, P.; Havel, P. J.; Griffey, S.; Knaus, H. G.; Nepom, G. T.; Gutman, G. A.; Calabresi, P. A.; Chandy, K. G. Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proc. Natl. Acad. Sci. USA, 2006, 103 (46), 17414-17419.
218. Rus, H.; Pardo, C. A.; Hu, L.; Darrah, E.; Cudrici, C.; Niculescu, T.; Niculescu, F.; Mullen, K. M.; Allie, R.; Guo, L.; Wulff, H.; Beeton, C.; Judge, S. I.; Kerr, D. A.; Knaus, H. G.; Chandy, K. G.; Calabresi, P. A. The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain. Proc. Natl. Acad. Sci. USA, 2005, 102 (31), 11094-11099.
219. Nicolaou, S. A.; Szigligeti, P.; Neumeier, L.; Lee, S. M.; Duncan, H. J.; Kant, S. K.; Mongey, A. B.; Filipovich, A. H.; Conforti, L. Altered dynamics of Kv1.3 channel compartmentalization in the immunological synapse in systemic lupus erythematosus. J. Immunol., 2007, 179 (1), 346-356.
220. Matheu, M. P.; Beeton, C.; Garcia, A.; Chi, V.; Rangaraju, S.; Safrina, O.; Monaghan, K.; Uemura, M. I.; Li, D.; Pal, S.; de la Maza, L. M.; Monuki, E.; Flugel, A.; Pennington, M. W.; Parker, I.; Chandy, K. G.; Cahalan, M. D. Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block. Immunity, 2008, 29 (4), 602-614.
221. Bezerra, E. L.; Vilar, M. J.; da Trindade Neto, P. B.; Sato, E. I. Double-blind, randomized, controlled clinical trial of clofazimine compared with chloroquine in patients with systemic lupus erythematosus. Arthritis Rheum., 2005, 52 (10), 3073-3078.
222. Mackey, J. P.; Barnes, J. Clofazimine in the treatment of discoid lupus erythematosus. Br. J. Dermatol., 1974, 91 (1), 93-96.
223. Chuaprapaisilp, T.; Piamphongsant, T. Treatment of pustular psoriasis with clofazimine. Br. J. Dermatol., 1978, 99 (3), 303-305.
224. Lee, S. J.; Wegner, S. A.; McGarigle, C. J.; Bierer, B. E.; Antin, J. H. Treatment of chronic graft-versus-host disease with clofazimine. Blood, 1997, 89 (7), 2298-2302.
225. Ren, Y. R.; Pan, F.; Parvez, S.; Fleig, A.; Chong, C. R.; Xu, J.; Dang, Y.; Zhang, J.; Jiang, H.; Penner, R.; Liu, J. O. Clofazimine inhibits human Kv1.3 potassium channel by perturbing calcium oscillation in T lymphocytes. PLoS One, 2008, 3 (12), e4009.
226. Goodman, A. D.; Brown, T. R.; Krupp, L. B.; Schapiro, R. T.; Schwid, S. R.; Cohen, R.; Marinucci, L. N.; Blight, A. R. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet, 2009, 373 (9665), 732-738.
227. Vollmer, T.; Blight, A. R.; Henney, H. R., 3rd. Steady-state pharmacokinetics and tolerability of orally administered fampridine sustained-release 10-mg tablets in patients with multiple sclerosis: a 2-week, open-label, follow-up study. Clin. Ther., 2009, 31 (10), 2215-2223.
228. DeCoursey, T. E.; Chandy, K. G.; Gupta, S.; Cahalan, M. D. Voltage-gated K+ channels in human T lymphocytes: a role in mitogenesis? Nature, 1984, 307 (5950), 465-468.
229. Beeton, C.; Barbaria, J.; Giraud, P.; Devaux, J.; Benoliel, A. M.; Gola, M.; Sabatier, J. M.; Bernard, D.; Crest, M.; Beraud, E. Selective blocking of voltage-gated K+ channels improves experimental autoimmune encephalomyelitis and inhibits T cell activation. J. Immunol., 2001, 166 (2), 936-944.
230. Valverde, P.; Kawai, T.; Taubman, M. A. Selective blockade of voltage-gated potassium channels reduces inflammatory bone resorption in experimental periodontal disease. J. Bone Miner. Res., 2004, 19 (1), 155-164.
231. Pennington, M. W.; Beeton, C.; Galea, C. A.; Smith, B. J.; Chi, V.; Monaghan, K. P.; Garcia, A.; Rangaraju, S.; Giuffrida, A.; Plank, D.; Crossley, G.; Nugent, D.; Khaytin, I.; Lefievre, Y.; Peshenko, I.; Dixon, C.; Chauhan, S.; Orzel, A.; Inoue, T.; Hu, X.; Moore, R. V.; Norton, R. S.; Chandy, K. G. Engineering a stable and selective peptide blocker of the Kv1.3 channel in T lymphocytes. Mol. Pharmacol., 2009, 75 (4), 762-773.
232. Rangaraju, S.; Khoo, K. K.; Feng, Z.; Crossley, G.; Nugent, D.; Khaytin, I.; Chi, V.; Pham, C.; Calabresi, P.; Pennington, M. W.; Norton, R. S.; Chandy, K. G. Potassium channel modulation by a toxin domain in matrix metalloprotease 23. J. Biol. Chem., 2010, 285(12):9124-9136.
233. Breland, A. E.; Currier, R. D. Scorpion venom and multiple sclerosis. Lancet, 1983, 2 (8357), 1021-1021.
234. Beeton, C.; Wulff, H.; Barbaria, J.; Clot-Faybesse, O.; Pennington, M.; Bernard, D.; Cahalan, M. D.; Chandy, K. G.; Beraud, E. Selective blockade of T lymphocyte K(+) channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis. Proc. Natl. Acad Sci. USA, 2001, 98 (24), 13942-13947.
235. Koo, G. C.; Blake, J. T.; Talento, A.; Nguyen, M.; Lin, S.; Sirotina, A.; Shah, K.; Mulvany, K.; Hora, D., Jr.; Cunningham, P.; Wunderler, D. L.; McManus, O. B.; Slaughter, R.; Bugianesi, R.; Felix, J.; Garcia, M.; Williamson, J.; Kaczorowski, G.; Sigal, N. H.; Springer, M. S.; Feeney, W. Blockade of the voltage-gated potassium channel Kv1.3 inhibits immune responses in vivo. J. Immunol., 1997, 158 (11), 5120-5128.
236. Nashmi, R.; Jones, O. T.; Fehlings, M. G. Abnormal axonal physiology is associated with altered expression and distribution of Kv1.1 and Kv1.2 K+ channels after chronic spinal cord injury. Eur. J. Neurosci., 2000, 12 (2), 491-506.
237. Wang, H.; Allen, M. L.; Grigg, J. J.; Noebels, J. L.; Tempel, B. L. Hypomyelination alters K+ channel expression in mouse mutants shiverer and Trembler. Neuron, 1995, 15 (6), 1337-1347.
238. Rasband, M. N.; Trimmer, J. S.; Schwarz, T. L.; Levinson, S. R.; Ellisman, M. H.; Schachner, M.; Shrager, P. Potassium channel distribution, clustering, and function in remyelinating rat axons. J. Neurosci., 1998, 18 (1), 36-47.
239. Devaux, J.; Forni, C.; Beeton, C.; Barbaria, J.; Beraud, E.; Gola, M.; Crest, M. Myelin basic protein-reactive T cells induce conduction failure in vivo but not in vitro. Neuroreport, 2003, 14 (3), 317-320.
240. Heininger, K.; Fierz, W.; Schafer, B.; Hartung, H. P.; Wehling, P.; Toyka, K. V. Electrophysiological investigations in adoptively transferred experimental autoimmune encephalomyelitis in the Lewis rat. Brain, 1989, 112 (Pt 2), 537-552.
241. Devaux, J.; Beeton, C.; Beraud, E.; Crest, M. Ion channels and demyelination: basis of a treatment of experimental autoimmune encephalomyelitis (EAE) by potassium channel blockers. Rev. Neurol., (Paris) 2004, 160 (5 Pt 2), S16-27.
242. Beraud, E.; Viola, A.; Regaya, I.; Confort-Gouny, S.; Siaud, P.; Ibarrola, D.; Le Fur, Y.; Barbaria, J.; Pellissier, J. F.; Sabatier, J. M.; Medina, I.; Cozzone, P. J. Block of neural Kv1.1 potassium channels for neuroinflammatory disease therapy. Ann. Neurol., 2006, 60 (5), 586-596.
243. Veh, R. W.; Lichtinghagen, R.; Sewing, S.; Wunder, F.; Grumbach, I. M.; Pongs, O. Immunohistochemical localization of five members of the Kv1 channel subunits: contrasting subcellular locations and neuron-specific co-localizations in rat brain. Eur. J. Neurosci., 1995, 7 (11), 2189-21205.
244. Angulo, E.; Noe, V.; Casado, V.; Mallol, J.; Gomez-Isla, T.; Lluis, C.; Ferrer, I.; Ciudad, C. J.; Franco, R. Up-regulation of the Kv3.4 potassium channel subunit in early stages of Alzheimer's disease. J. Neurochem., 2004, 91 (3), 547-57.
245. Pannaccione, A.; Boscia, F.; Scorziello, A.; Adornetto, A.; Castaldo, P.; Sirabella, R.; Taglialatela, M.; Di Renzo, G. F.; Annunziato, L. Up-regulation and increased activity of Kv3.4 channels and their accessory subunit MinK-related peptide 2 induced by amyloid peptide are involved in apoptotic neuronal death. Mol. Pharmacol., 2007, 72 (3), 665-673.
246. Yu, H. B.; Li, Z. B.; Zhang, H. X.; Wang, X. L. Role of potassium channels in Abeta(1-40)-activated apoptotic pathway in cultured cortical neurons. J. Neurosci. Res., 2006, 84 (7), 1475-1484.
247. Yeung, S. Y.; Thompson, D.; Wang, Z.; Fedida, D.; Robertson, B. Modulation of Kv3 subfamily potassium currents by the sea anemone toxin BDS: significance for CNS and biophysical studies. J. Neurosci., 2005, 25 (38), 8735-8745.
248. Baranauskas, G.; Tkatch, T.; Nagata, K.; Yeh, J. Z.; Surmeier, D. J. Kv3.4 subunits enhance the repolarizing efficiency of Kv3.1 channels in fast-spiking neurons. Nat. Neurosci., 2003, 6 (3), 258-266.
249. Bergman, H.; Wichmann, T.; Karmon, B.; DeLong, M. R. The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism. J. Neurophysiol., 1994, 72 (2), 507-520.
250. Lozano, A. M.; Dostrovsky, J.; Chen, R.; Ashby, P. Deep brain stimulation for Parkinson's disease: disrupting the disruption. Lancet Neurol., 2002, 1 (4), 225-231.
251. DeLong, M. R.; Wichmann, T., Deep brain stimulation for Parkinson's disease. Ann. Neurol., 2001, 49 (2), 142-143.
252. Bauer, C. K.; Wulfsen, I.; Schafer, R.; Glassmeier, G.; Wimmers, S.; Flitsch, J.; Ludecke, D. K.; Schwarz, J. R. HERG K(+) currents in human prolactin-secreting adenoma cells. Pflugers Arch., 2003, 445 (5), 589-600.
253. Sanguinetti, M. C.; Jiang, C.; Curran, M. E.; Keating, M. T. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell, 1995, 81 (2), 299-307.
254. Sanguinetti, M. C.; Tristani-Firouzi, M. HERG potassium channels and cardiac arrhythmia. Nature, 2006, 440 (7083), 463-469.
255. Vandenberg, J. I.; Torres, A. M.; Campbell, T. J.; Kuchel, P. W. The HERG K+ channel: progress in understanding the molecular basis of its unusual gating kinetics. Eur. Biophys. J., 2004, 33 (2), 89-97.
256. Curran, M. E.; Splawski, I.; Timothy, K. W.; Vincent, G. M.; Green, E. D.; Keating, M. T. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell, 1995, 80 (5), 795-803.
257. Tseng, G. N. I(Kr): the hERG channel. J. Mol. Cell. Cardiol. 2001, 33 (5), 835-849.
258. Arcangeli, A. Expression and role of hERG channels in cancer cells. Novartis Found Symp., 2005, 266, 225-232; discussion 232-234.
259. Crociani, O.; Guasti, L.; Balzi, M.; Becchetti, A.; Wanke, E.; Olivotto, M.; Wymore, R. S.; Arcangeli, A. Cell cycle-dependent expression of HERG1 and HERG1B isoforms in tumor cells. J. Biol. Chem., 2003, 278 (5), 2947-2955.
260. Lastraioli, E.; Guasti, L.; Crociani, O.; Polvani, S.; Hofmann, G.; Witchel, H.; Bencini, L.; Calistri, M.; Messerini, L.; Scatizzi, M.; Moretti, R.; Wanke, E.; Olivotto, M.; Mugnai, G.; Arcangeli, A. Herg1 gene and HERG1 protein are overexpressed in colorectal cancers and regulate cell invasion of tumor cells. Cancer Res., 2004, 64 (2), 606-611.
261. Masi, A.; Becchetti, A.; Restano-Cassulini, R.; Polvani, S.; Hofmann, G.; Buccoliero, A. M.; Paglierani, M.; Pollo, B.; Taddei, G. L.; Gallina, P.; Di Lorenzo, N.; Franceschetti, S.; Wanke, E.; Arcangeli, A. HERG1 channels are overexpressed in glioblastoma multiforme and modulate VEGF secretion in glioblastoma cell lines. Br. J. Cancer, 2005, 93 (7), 781-792.
262. Pillozzi, S.; Brizzi, M. F.; Bernabei, P. A.; Bartolozzi, B.; Caporale, R.; Basile, V.; Boddi, V.; Pegoraro, L.; Becchetti, A.; Arcangeli, A. VEGFR-1 (FLT-1), beta1 integrin, and hERG K+ channel for a macromolecular signaling complex in acute myeloid leukemia: role in cell migration and clinical outcome. Blood, 2007, 110 (4), 1238-1250.
263. Wang, X.; Hockerman, G. H.; Green, H. W., 3rd; Babbs, C. F.; Mohammad, S. I.; Gerrard, D.; Latour, M. A.; London, B.; Hannon, K. M.; Pond, A. L., Merg1a K+ channel induces skeletal muscle atrophy by activating the ubiquitin proteasome pathway. FASEB J., 2006, 20 (9), 1531-1533.
264. Ganapathi, S. B.; Kester, M.; Elmslie, K. S. State-dependent block of HERG potassium channels by R-roscovitine: implications for cancer therapy. Am. J. Physiol. Cell Physiol., 2009, 296 (4), C701-C710.
265. Milnes, J. T.; Dempsey, C. E.; Ridley, J. M.; Crociani, O.; Arcangeli, A.; Hancox, J. C.; Witchel, H. J. Preferential closed channel blockade of HERG potassium currents by chemically synthesised BeKm-1 scorpion toxin. FEBS Lett., 2003, 547 (1/3), 20-26.
266. Cauwels, A.; Brouckaert, P. Critical role for small and large conductance calcium-dependent potassium channels in endotoxemia and TNF toxicity. Shock, 2008, 29 (5), 577-582.
267. Weaver, A. K.; Bomben, V. C.; Sontheimer, H. Expression and function of calcium-activated potassium channels in human glioma cells. Glia, 2006, 54 (3), 223-233.
268. Weaver, A. K.; Liu, X.; Sontheimer, H., Role for calcium-activated potassium channels (BK) in growth control of human malignant glioma cells. J. Neurosci. Res., 2004, 78 (2), 224-2234.
269. Galvez, A.; Gimenez-Gallego, G.; Reuben, J. P.; Roy-Contancin, L.; Feigenbaum, P.; Kaczorowski, G. J.; Garcia, M. L. Purification and characterization of a unique, potent, peptidyl probe for the high conductance calcium-activated potassium channel from venom of the scorpion Buthus tamulus. J. Biol. Chem., 1990, 265 (19), 11083-11090.
270. Yao, J.; Chen, X.; Li, H.; Zhou, Y.; Yao, L.; Wu, G.; Zhang, N.; Zhou, Z.; Xu, T.; Wu, H.; Ding, J. BmP09, a long chain scorpion peptide blocker of BK channels. J. Biol. Chem., 2005, 280 (15), 14819-14828.
271. Garcia-Valdes, J.; Zamudio, F. Z.; Toro, L.; Possani, L. D. Slotoxin, alphaKTx1.11, a new scorpion peptide blocker of MaxiK channels that differentiates between alpha and alpha+beta (beta1 or beta4) complexes. FEBS Lett., 2001, 505 (3), 369-373.
272. Shah, M.; Haylett, D. G. The pharmacology of hSK1 Ca2+- activated K+ channels expressed in mammalian cell lines. Br. J. Pharmacol., 2000, 129 (4), 627-630.
273. Strobaek, D.; Jorgensen, T. D.; Christophersen, P.; Ahring, P. K.; Olesen, S. P. Pharmacological characterization of smallconductance Ca(2+)-activated K+ channels stably expressed in HEK 293 cells. Br. J. Pharmacol., 2000, 129 (5), 991-999.
274. Shakkottai, V. G.; Regaya, I.; Wulff, H.; Fajloun, Z.; Tomita, H.; Fathallah, M.; Cahalan, M. D.; Gargus, J. J.; Sabatier, J. M.; Chandy, K. G. Design and characterization of a highly selective peptide inhibitor of the small conductance calcium-activated K+ channel, SkCa2. J. Biol. Chem., 2001, 276 (46), 43145-43151.
275. Jager, H.; Adelman, J. P.; Grissmer, S. SK2 encodes the apaminsensitive Ca(2+)-activated K(+) channels in the human leukemic T cell line, Jurkat. FEBS Lett., 2000, 469 (2-3), 196-202.
276. Kohler, M.; Hirschberg, B.; Bond, C. T.; Kinzie, J. M.; Marrion, N. V.; Maylie, J.; Adelman, J. P. Small-conductance, calciumactivated potassium channels from mammalian brain. Science, 1996, 273 (5282), 1709-17014.
277. Pedarzani, P.; D'Hoedt, D.; Doorty, K. B.; Wadsworth, J. D.; Joseph, J. S.; Jeyaseelan, K.; Kini, R. M.; Gadre, S. V.; Sapatnekar, S. M.; Stocker, M.; Strong, P. N. Tamapin, a venom peptide from the Indian red scorpion (Mesobuthus tamulus) that targets small conductance Ca2+-activated K+ channels and afterhyperpolarization currents in central neurons. J. Biol. Chem., 2002, 277 (48), 46101-46109.
278. Hosseini, R.; Benton, D. C.; Dunn, P. M.; Jenkinson, D. H.; Moss, G. W. SK3 is an important component of K+ channels mediating the afterhyperpolarization in cultured rat SCG neurones. J. Physiol., 2001, 535 (Pt 2), 323-334.
279. Castle, N. A.; London, D. O.; Creech, C.; Fajloun, Z.; Stocker, J. W.; Sabatier, J. M. Maurotoxin: a potent inhibitor of intermediate conductance Ca2+-activated potassium channels. Mol. Pharmacol., 2003, 63 (2), 409-418.
280. Rauer, H.; Lanigan, M. D.; Pennington, M. W.; Aiyar, J.; Ghanshani, S.; Cahalan, M. D.; Norton, R. S.; Chandy, K. G. Structure-guided transformation of charybdotoxin yields an analog that selectively targets Ca(2+)-activated over voltage-gated K+channels. J. Biol. Chem., 2000, 275 (2), 1201-1208.
281. Wulff, H.; Pennington, M. Targeting effector memory T-cells with Kv1.3 blockers. Curr. Opin. Drug Discov. Devel., 2007, 10 (4), 438-445.
282. Fanger, C. M.; Ghanshani, S.; Logsdon, N. J.; Rauer, H.; Kalman, K.; Zhou, J.; Beckingham, K.; Chandy, K. G.; Cahalan, M. D.; Aiyar, J. Calmodulin mediates calcium-dependent activation of the intermediate conductance KCa channel, IKCa1. J. Biol. Chem., 1999, 274 (9), 5746-57454.
283. Di, L.; Srivastava, S.; Zhdanova, O.; Ding, Y.; Li, Z.; Wulff, H.; Lafaille, M.; Skolnik, E. Y. Inhibition of the K+ channel KCa3.1 ameliorates T cell-mediated colitis. Proc. Natl. Acad. Sci. USA, 2010, 107(4):1541-1546.
284. Grgic, I.; Kiss, E.; Kaistha, B. P.; Busch, C.; Kloss, M.; Sautter, J.; Muller, A.; Kaistha, A.; Schmidt, C.; Raman, G.; Wulff, H.; Strutz, F.; Grone, H. J.; Kohler, R.; Hoyer, J. Renal fibrosis is attenuated by targeted disruption of KCa3.1 potassium channels. Proc. Natl. Acad. Sci. USA, 2009, 106 (34), 14518-14523.
285. Kohler, R.; Wulff, H.; Eichler, I.; Kneifel, M.; Neumann, D.; Knorr, A.; Grgic, I.; Kampfe, D.; Si, H.; Wibawa, J.; Real, R.; Borner, K.; Brakemeier, S.; Orzechowski, H. D.; Reusch, H. P.; Paul, M.; Chandy, K. G.; Hoyer, J. Blockade of the intermediateconductance calcium-activated potassium channel as a new therapeutic strategy for restenosis. Circulation, 2003, 108 (9), 1119-1125.
286. Reich, E. P.; Cui, L.; Yang, L.; Pugliese-Sivo, C.; Golovko, A.; Petro, M.; Vassileva, G.; Chu, I.; Nomeir, A. A.; Zhang, L. K.; Liang, X.; Kozlowski, J. A.; Narula, S. K.; Zavodny, P. J.; Chou, C. C. Blocking ion channel KCNN4 alleviates the symptoms of experimental autoimmune encephalomyelitis in mice. Eur. J. Immunol., 2005, 35 (4), 1027-1036.
287. Toyama, K.; Wulff, H.; Chandy, K. G.; Azam, P.; Raman, G.; Saito, T.; Fujiwara, Y.; Mattson, D. L.; Das, S.; Melvin, J. E.; Pratt, P. F.; Hatoum, O. A.; Gutterman, D. D.; Harder, D. R.; Miura, H. The intermediate-conductance calcium-activated potassium channel KCa3.1 contributes to atherogenesis in mice and humans. J. Clin. Invest., 2008, 118 (9), 3025-3037.
288. Grgic, I.; Wulff, H.; Eichler, I.; Flothmann, C.; Kohler, R.; Hoyer, J. Blockade of T-lymphocyte KCa3.1 and Kv1.3 channels as novel immunosuppression strategy to prevent kidney allograft rejection. Transplant Proc., 2009, 41 (6), 2601-2606.
289. Fay, A. J.; Qian, X.; Jan, Y. N.; Jan, L. Y. SK channels mediate NADPH oxidase-independent reactive oxygen species production and apoptosis in granulocytes. Proc. Natl. Acad. Sci. USA, 2006, 103 (46), 17548-17553.
290. DeBin, J. A.; Strichartz, G. R. Chloride channel inhibition by the venom of the scorpion Leiurus quinquestriatus. Toxicon, 1991, 29 (11), 1403-1408.
291. Ullrich, N.; Bordey, A.; Gillespie, G. Y.; Sontheimer, H. Expression of voltage-activated chloride currents in acute slices of human gliomas. Neuroscience, 1998, 83 (4), 1161-1173.
292. Ullrich, N.; Sontheimer, H. Biophysical and pharmacological characterization of chloride currents in human astrocytoma cells. Am. J. Physiol., 1996, 270 (5 Pt 1), C1511-21.
293. Soroceanu, L.; Gillespie, Y.; Khazaeli, M. B.; Sontheimer, H. Use of chlorotoxin for targeting of primary brain tumors. Cancer Res., 1998, 58 (21), 4871-4879.
294. Soroceanu, L.; Manning, T. J., Jr.; Sontheimer, H. Modulation of glioma cell migration and invasion using Cl(-) and K(+) ion channel blockers. J. Neurosci., 1999, 19 (14), 5942-5954.
295. McFerrin, M. B.; Sontheimer, H. A role for ion channels in glioma cell invasion. Neuron Glia Biol., 2006, 2 (1), 39-49.
296. Mamelak, A. N.; Jacoby, D. B. Targeted delivery of antitumoral therapy to glioma and other malignancies with synthetic chlorotoxin (TM-601). Expert Opin. Drug Deliv., 2007, 4 (2), 175-186.
297. Diochot, S.; Salinas, M.; Baron, A.; Escoubas, P.; Lazdunski, M. Peptides inhibitors of acid-sensing ion channels. Toxicon, 2007, 49 (2), 271-284.
298. Jasti, J.; Furukawa, H.; Gonzales, E. B.; Gouaux, E. Structure of acid-sensing ion channel 1 at 1.9 A resolution and low pH. Nature, 2007, 449 (7160), 316-323.
299. Friese, M. A.; Craner, M. J.; Etzensperger, R.; Vergo, S.; Wemmie, J. A.; Welsh, M. J.; Vincent, A.; Fugger, L. Acid-sensing ion channel-1 contributes to axonal degeneration in autoimmune inflammation of the central nervous system. Nat. Med., 2007, 13 (12), 1483-1489.
300. Deval, E.; Noel, J.; Lay, N.; Alloui, A.; Diochot, S.; Friend, V.; Jodar, M.; Lazdunski, M.; Lingueglia, E. ASIC3, a sensor of acidic and primary inflammatory pain. EMBO J., 2008, 27 (22), 3047-3055.
301. Ikeuchi, M.; Kolker, S. J.; Sluka, K. A. Acid-sensing ion channel 3 expression in mouse knee joint afferents and effects of carrageenan-induced arthritis. J. Pain, 2009, 10 (3), 336-342.
302. Mazzuca, M.; Heurteaux, C.; Alloui, A.; Diochot, S.; Baron, A.; Voilley, N.; Blondeau, N.; Escoubas, P.; Gelot, A.; Cupo, A.; Zimmer, A.; Zimmer, A. M.; Eschalier, A.; Lazdunski, M. A tarantula peptide against pain via ASIC1a channels and opioid mechanisms. Nat. Neurosci., 2007, 10 (8), 943-945.
303. Diochot, S.; Baron, A.; Rash, L. D.; Deval, E.; Escoubas, P.; Scarzello, S.; Salinas, M.; Lazdunski, M. A new sea anemone peptide, APETx2, inhibits ASIC3, a major acid-sensitive channel in sensory neurons. EMBO J., 2004, 23 (7), 1516-1525.
304. Bowman, C. L.; Gottlieb, P. A.; Suchyna, T. M.; Murphy, Y. K.; Sachs, F. Mechanosensitive ion channels and the peptide inhibitor GsMTx-4: history, properties, mechanisms and pharmacology. Toxicon, 2007, 49 (2), 249-270.
305. Park, S. P.; Kim, B. M.; Koo, J. Y.; Cho, H.; Lee, C. H.; Kim, M.; Na, H. S.; Oh, U. A tarantula spider toxin, GsMTx4, reduces mechanical and neuropathic pain. Pain, 2008, 137 (1), 208-217.
306. Jimenez, E. C.; Donevan, S.; Walker, C.; Zhou, L. M.; Nielsen, J.; Cruz, L. J.; Armstrong, H.; White, H. S.; Olivera, B. M. Conantokin-L, a new NMDA receptor antagonist: determinants for anticonvulsant potency. Epilepsy Res., 2002, 51 (1-2), 73-80.
307. Donevan, S. D.; McCabe, R. T. Conantokin G is an NR2Bselective competitive antagonist of N-methyl-D-aspartate receptors. Mol. Pharmacol., 2000, 58 (3), 614-623.
308. Haack, J. A.; Rivier, J.; Parks, T. N.; Mena, E. E.; Cruz, L. J.; Olivera, B. M., Conantokin T. A gamma-carboxyglutamate containing peptide with N-methyl-d-aspartate antagonist activity. J. Biol. Chem., 1990, 265 (11), 6025-6029.
309. Layer, R. T.; Wagstaff, J. D.; White, H. S. Conantokins: peptide antagonists of NMDA receptors. Curr. Med. Chem., 2004, 11 (23), 3073-3084.
310. Williams, A. J.; Dave, J. R.; Phillips, J. B.; Lin, Y.; McCabe, R. T.; Tortella, F. C. Neuroprotective efficacy and therapeutic window of the high-affinity N-methyl-D-aspartate antagonist conantokin-G: in vitro (primary cerebellar neurons) and in vivo (rat model of transient focal brain ischemia) studies. J. Pharmacol. Exp. Ther., 2000, 294 (1), 378-386.
311. Teichert, R. W.; Jimenez, E. C.; Twede, V.; Watkins, M.; Hollmann, M.; Bulaj, G.; Olivera, B. M. Novel conantokins from Conus parius venom are specific antagonists of N-methyl-Daspartate receptors. J. Biol. Chem., 2007, 282 (51), 36905-36913.
312. Wei, J.; Dong, M.; Xiao, C.; Jiang, F.; Castellino, F. J.; Prorok, M.; Dai, Q. Conantokins and variants derived from cone snail venom inhibit naloxone-induced withdrawal jumping in morphinedependent mice. Neurosci. Lett., 2006, 405 (1-2), 137-141.
313. McIntosh, J. M.; Olivera, B. M.; Cruz, L. J.; Gray, W. R. Gammacarboxyglutamate in a neuroactive toxin. J. Biol. Chem., 1984, 259 (23), 14343-14346.
314. Barton, M. E.; White, H. S., The effect of CGX-1007 and CI-1041, novel NMDA receptor antagonists, on kindling acquisition and expression. Epilepsy Res., 2004, 59 (1), 1-12.
315. Wittekindt, B.; Malany, S.; Schemm, R.; Otvos, L.; Maccecchini, M. L.; Laube, B.; Betz, H. Point mutations identify the glutamate binding pocket of the N-methyl-D-aspartate receptor as major site of conantokin-G inhibition. Neuropharmacology, 2001, 41 (6), 753-761.
316. Klein, R. C.; Galdzicki, Z.; Castellino, F. J. Inhibition of NMDAinduced currents by conantokin-G and conantokin-T in cultured embryonic murine hippocampal neurons. Neuropharmacology, 1999, 38 (12), 1819-1829.
317. White, H. S.; McCabe, R. T.; Armstrong, H.; Donevan, S. D.; Cruz, L. J.; Abogadie, F. C.; Torres, J.; Rivier, J. E.; Paarmann, I.; Hollmann, M.; Olivera, B. M. In vitro and in vivo characterization of conantokin-R, a selective NMDA receptor antagonist isolated from the venom of the fish-hunting snail Conus radiatus. J. Pharmacol. Exp. Ther., 2000, 292 (1), 425-432.